CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.
It is the first glucagon therapy approved for this indication that is administrable without an injection.
From the Journals
Serious complications and death are likely if Fournier gangrene is not recognized.
“Increasing the availability of glucagon in the prehospital setting will likely result in reduced cost burden and adverse consequences of severe...
Dr. Francine Pearce discusses the correlation between a spicy snack teens love and visits to the ED.
Commentaries on cases involving a 26-year-old woman with a history of chronic constipation and a 27-year-old man with a 3-day history of severe...